TY - JOUR
T1 - Comparison of β2-microglobulin serum level between Alzheimer’s patients, cognitive healthy and mild cognitive impaired individuals
AU - Dominici, Roberto
AU - Finazzi, Dario
AU - Polito, Letizia
AU - Oldoni, Emanuela
AU - Bugari, Giovanna
AU - Montanelli, Alessandro
AU - Scarpini, Elio
AU - Galimberti, Daniela
AU - Guaita, Antonio
PY - 2018
Y1 - 2018
N2 - Background: Several studies performed in the last years on the brain, showed that beta2-microglobulin (β2m) and MHC can act independently of their canonical immune function to regulate normal brain development, synaptic plasticity and behaviour. Increased systemic levels of soluble β2m have been implicated in cognitive impairments like that associated with chronic haemodialysis, or aortic valve replacement. Increased soluble β2m has also been detected in the cerebral spinal fluid (CSF) of patients with HIV-associated dementia and Alzheimer’s disease (AD). Objective: To compare plasma β2m levels in healthy subjects and subjects with dementia or cognitive impairment. Methods: We measured the concentration of β2m in a cohort of 245 individuals and compared sex matched, cognitive healthy individuals. Results: We found higher levels of β2m in AD patients compared to non-AD MCI and healthy controls (2063 ng/mL ±852 versus 1613 ± 503 and 1832 ± 382 ng/mL, p< 0.001 and <0.033, respectively), while there was no difference between mild cognitive impairment (MCI) and healthy controls (p > 0.05). Conclusions: Our data confirm that β2m could play a role in AD. However, a replication study in an independent cohort would be necessary to confirm our preliminary results.
AB - Background: Several studies performed in the last years on the brain, showed that beta2-microglobulin (β2m) and MHC can act independently of their canonical immune function to regulate normal brain development, synaptic plasticity and behaviour. Increased systemic levels of soluble β2m have been implicated in cognitive impairments like that associated with chronic haemodialysis, or aortic valve replacement. Increased soluble β2m has also been detected in the cerebral spinal fluid (CSF) of patients with HIV-associated dementia and Alzheimer’s disease (AD). Objective: To compare plasma β2m levels in healthy subjects and subjects with dementia or cognitive impairment. Methods: We measured the concentration of β2m in a cohort of 245 individuals and compared sex matched, cognitive healthy individuals. Results: We found higher levels of β2m in AD patients compared to non-AD MCI and healthy controls (2063 ng/mL ±852 versus 1613 ± 503 and 1832 ± 382 ng/mL, p< 0.001 and <0.033, respectively), while there was no difference between mild cognitive impairment (MCI) and healthy controls (p > 0.05). Conclusions: Our data confirm that β2m could play a role in AD. However, a replication study in an independent cohort would be necessary to confirm our preliminary results.
KW - Alzheimer disease
KW - mild cognitive impairment
KW - serum biomarkers
KW - β2-microglobulin
UR - http://www.scopus.com/inward/record.url?scp=85047243188&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85047243188&partnerID=8YFLogxK
U2 - 10.1080/1354750X.2018.1468825
DO - 10.1080/1354750X.2018.1468825
M3 - Article
AN - SCOPUS:85047243188
VL - 23
SP - 603
EP - 608
JO - Biomarkers
JF - Biomarkers
SN - 1354-750X
IS - 6
ER -